Immunic, Inc.

NasdaqCM:IMUX 株式レポート

時価総額：US$203.8m

Immunic マネジメント

マネジメント 基準チェック /34

Immunicの CEO はDaniel Vittで、 Apr2019年に任命され、 の在任期間は 7.08年です。 の年間総報酬は$ 2.31Mで、 27.1%給与と72.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.29%を直接所有しており、その価値は$ 586.25K 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と5.5年です。

主要情報

Daniel Vitt

最高経営責任者

US$2.3m

報酬総額

CEO給与比率27.05%
CEO在任期間7.1yrs
CEOの所有権0.3%
経営陣の平均在職期間4.8yrs
取締役会の平均在任期間5.5yrs

経営陣の近況

Recent updates

分析記事 • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
分析記事 • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
分析記事 • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO報酬分析

Immunic の収益と比較して、Daniel Vitt の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$2mUS$625k

-US$97m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$102m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$3mUS$610k

-US$101m

Sep 30 2024n/an/a

-US$97m

Jun 30 2024n/an/a

-US$95m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$1mUS$585k

-US$94m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$3mUS$520k

-US$120m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$2mUS$399k

-US$93m

Sep 30 2021n/an/a

-US$83m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$1mUS$381k

-US$44m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$39m

Dec 31 2019US$2mUS$202k

-US$35m

報酬と市場: Danielの 総報酬 ($USD 2.31M ) は、 US市場 ($USD 1.59M ) の同規模の企業の平均を上回っています。

報酬と収益: Danielの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Daniel Vitt (57 yo)

7.1yrs
在職期間
US$2,311,272
報酬

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.2k
Jason Tardio
COO & President1.8yrsUS$1.21m0.0092%
$ 18.7k
Glenn Whaley
Chief Financial Officer6.1yrsUS$1.07m0.070%
$ 142.9k
Hella Kohlhof
Chief Scientific Officer9.3yrsデータなしデータなし
Jessica Breu
Vice President of Investor Relations & Communicationsno dataデータなしデータなし
Inderpal Singh
General Counsel4.9yrsデータなしデータなし
Patrick Walsh
Chief Business Officer4.6yrsデータなしデータなし
Werner Gladdines
Chief Development Officer1.8yrsデータなしデータなし
Michael A. Panzara
Chief Medical Officerless than a yearデータなしデータなし
4.8yrs
平均在職期間
54yo
平均年齢

経験豊富な経営陣: IMUXの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.2k
Barclay Phillips
Lead Independent Director6.5yrsUS$171.98k0.11%
$ 233.3k
Michael Bonney
Chair of the Boardno dataデータなしデータなし
Tamar Howson
Independent Director6.6yrsUS$149.82k0.11%
$ 233.3k
Jorg Neermann
Independent Director7.1yrsUS$156.98k0.15%
$ 299.2k
Paul Utz
Member of Scientific Medical Advisory Board5.5yrsデータなしデータなし
Duane Nash
Director7.3yrsUS$982.95k0.026%
$ 53.9k
Bruce Sands
Member of Scientific Medical Advisory Board5.5yrsデータなしデータなし
Fred Lublin
Member of Scientific Medical Advisory Board5.5yrsデータなしデータなし
Richard Rudick
Independent Director3.1yrsUS$149.48k0.17%
$ 344.6k
Jon Congleton
Independent Directorless than a yearデータなしデータなし
Simona Skerjanec
Independent Director1.8yrsUS$149.14kデータなし
5.5yrs
平均在職期間
62yo
平均年齢

経験豊富なボード: IMUXの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/31 16:32
終値2026/05/29 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Immunic, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets